Evergaze develops seeBOOST®, a novel and proprietary electronic wearable medical device for improving the vision of persons coping with Age-related Macular Degeneration (AMD) and Diabetic Retinopathy (DR). seeBOOST overcomes the significant drawbacks of all currently marketed vision assistive devices, whether head- or spectacle-mounted, handheld or implanted. seeBOOST successfully addresses these patients' primary need: to better see all day while undertaking a variety of normal-life tasks. The proprietary, vastly superior and cost effective technology empowers Evergaze to own the unserved and growing market for AMD and DR visual assistive devices. In the U.S. today, over 2.2 Million persons with AMD and at least 750,000 persons with DR could beneficially use seeBOOST. This market is growing due to the aging population and the increased prevalence of diabetes.